arrow
K

Kathleen I. Pritchard

canadian cancer trials group, kingston, ontario, canada
H指数:99
被引数:5.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic value of patient-reported depression in women with hormone-responsive early breast cancer in TEXT and SOFT

TEXT和SOFT研究中激素受体阳性早期乳腺癌女性患者报告抑郁的预后价值

Cancer
IF5.1
2025-09-230
PRE
Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy-a sub-analysis of the ALTTO study
2022-09-011
OA
Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies

富含DNA修复缺陷的晚期实体瘤患者CX-5461的I期CCTG IND.231试验结果

2022-06-2463
OAAI
Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)Presented at the 2017 annual meeting of the American Society of Clinical Oncology

在美国临床肿瘤学会2017年会上发表的国际III期ALTTO试验 (BIG 2-06/Alliance N063D) 的最新结果

2021-05-0115
OAAI
Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx
2020-06-1065
OA
Factors associated with endocrine therapy adherence among post-menopausal women treated for early-stage breast cancer in Ontario, Canada

加拿大安大略省接受早期乳腺癌治疗的绝经后妇女内分泌治疗依从性的相关因素

2019-10-0120
PREAI
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer
2019-06-20367
OAAI
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37298 women with early breast cancer in 26 randomised trials

通过更频繁的给药或序贯方案增加化疗的剂量强度: 对26项随机试验中37298名早期乳腺癌女性患者的患者水平荟萃分析

LANCET
IF88.5
2019-04-01279
OAAI